PharmaCyte Biotech (NASDAQ:PMCB) Releases Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) released its quarterly earnings data on Monday. The company reported ($0.10) EPS for the quarter, Zacks reports.

PharmaCyte Biotech Price Performance

NASDAQ PMCB remained flat at $1.58 on Monday. The company’s stock had a trading volume of 1,528 shares, compared to its average volume of 24,252. PharmaCyte Biotech has a one year low of $1.39 and a one year high of $2.58. The firm has a fifty day simple moving average of $1.65 and a two-hundred day simple moving average of $1.70. The company has a market cap of $10.85 million, a PE ratio of 2.98 and a beta of -0.25.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.